Display options
Cite
Chung KJ, Chung BI. Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms. Int Neurourol J. 2017;21(2):97-101doi: 10.5213/inj.1734928.464.
Chung, K. J., & Chung, B. I. (2017). Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms. International neurourology journal, 21(2), 97-101. https://doi.org/10.5213/inj.1734928.464
Chung, Kyung Jin, and Chung, Benjamin I. "Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms." International neurourology journal vol. 21,2 (2017): 97-101. doi: https://doi.org/10.5213/inj.1734928.464
Chung KJ, Chung BI. Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms. Int Neurourol J. 2017 Jun;21(2):97-101. doi: 10.5213/inj.1734928.464. Epub 2017 Jun 21. PMID: 28673067; PMCID: PMC5497200.
Copy Download .nbib Format: NLM
Share it on

Int Neurourol J. 2017 Jun;21(2):97-101. doi: 10.5213/inj.1734928.464. Epub 2017 Jun 21.

Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms.

International neurourology journal

Kyung Jin Chung, Benjamin I Chung

Affiliations

  1. Department of Urology, Stanford University School of Medicine, CA, USA.

PMID: 28673067 PMCID: PMC5497200 DOI: 10.5213/inj.1734928.464

Abstract

New drug development is a high-risk venture, but if successful, will bring great revenues to those willing to accept the risk. In the field of urology, in particular for lower urinary tract symptoms (LUTS), the recent successful landing of drugs (e.g., mirabegron, botulinum toxin A, and tadalafil) has resulted in increased interest in new drug development. Benign prostatic hyperplasia and overactive bladder syndrome, representative LUTS diseases, are attractive targets because of their prevalence and market size in the field of urology. Additionally, the awareness about new stream of research is very important not only because of the market size and economic factors, but also because to keep steady attention to these research for the researcher's. We have reviewed a selection of new drugs currently under development for the treatment of the two aforementioned diseases and hope to offer urologists an overview of the current situation and future directions in the field of urology.

Keywords: Clinical trials as topic; Lower Urinary Tract Symptoms; Prostatic Hyperplasia; Urinary Bladder, Overactive

References

  1. Clin Drug Investig. 2014 Jan;34(1):37-42 - PubMed
  2. Reprod Sci. 2014 Mar;21(3):363-71 - PubMed
  3. BJU Int. 2010 Oct;106(8):1114-27 - PubMed
  4. BJU Int. 2006 Dec;98(6):1310-4 - PubMed
  5. J Urol. 2013 Apr;189(4):1421-6 - PubMed
  6. Neurourol Urodyn. 2002;21(2):167-78 - PubMed
  7. Postgrad Med. 2012 May;124(3):16-27 - PubMed
  8. Handb Exp Pharmacol. 2011;(202):425-51 - PubMed
  9. J Acupunct Meridian Stud. 2012 Dec;5(6):319-22 - PubMed
  10. Int J Clin Pract. 2014 Aug;68(8):986-94 - PubMed
  11. Eur Urol. 2017 Apr;71(4):570-581 - PubMed
  12. Nat Rev Urol. 2011 Dec 13;9(1):30-40 - PubMed
  13. Res Rep Urol. 2014 Jul 12;6:67-70 - PubMed
  14. Urology. 2012 Jul;80(1):48-54 - PubMed
  15. Eur Urol. 2015 Mar;67(3):577-88 - PubMed
  16. Expert Opin Emerg Drugs. 2010 Jun;15(2):159-74 - PubMed
  17. J Immunol. 1992 Apr 1;148(7):2207-16 - PubMed
  18. Int J Clin Pract. 2015 Feb;69(2):242-50 - PubMed
  19. J Urol. 2014 Jan;191(1):253-60 - PubMed
  20. Rev Urol. 2005;7 Suppl 9:S3-S14 - PubMed
  21. Pain Physician. 2014 Jan-Feb;17(1):E45-60 - PubMed
  22. Korean J Urol. 2015 Oct;56(10):673-9 - PubMed
  23. Expert Opin Investig Drugs. 2014 Oct;23(10):1365-74 - PubMed
  24. Nat Rev Urol. 2015 Aug;12(8):461-71 - PubMed
  25. Womens Health (Lond). 2015 Jan;11(1):19-28 - PubMed
  26. Br J Pharmacol. 2009 Mar;156(5):807-17 - PubMed
  27. Expert Opin Pharmacother. 2016 Jul;17 (10 ):1317-25 - PubMed
  28. Bioorg Med Chem Lett. 2014 Mar 1;24(5):1327-33 - PubMed
  29. Br J Clin Pharmacol. 2011 Aug;72(2):197-204 - PubMed
  30. Am J Physiol Cell Physiol. 2008 May;294(5):C1206-14 - PubMed

Publication Types